Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2009

Quintás-Cardama Alfonso, Kantarjian Hagop M, Manshouri Taghi, Thomas Deborah, Cortes Jorge, Ravandi Farhad, Garcia-Manero Guillermo, Ferrajoli Alessandra, Bueso-Ramos Carlos, Verstovsek Srdan

Abstract excerpt

PURPOSE: To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF). PATIENTS AND METHODS: Forty patients with MF were treated. Therapy consisted of lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) on days 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Fibroblast Growth Factor 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Neutropenia

Share to Platelet-Derived Growth Factor

Share to Prednisone

Share to Primary Myelofibrosis

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 19720904
DOI: 10.1200/JCO.2009.22.6548
PMCID: PMC4879697

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19720904-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.PMID 19720904Read ↗

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Semantic proximity Read ↗

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

Rationale for combination therapy in myelofibrosis.Semantic proximity Read ↗

Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.Semantic proximity Read ↗

A phase-2 trial of low-dose pomalidomide in myelofibrosis.Semantic proximity Read ↗

Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromesSemantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Long-term results of prednisone treatment for the anemia of myelofibrosis.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.Semantic proximity Read ↗

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.